Patricia S. Andrews was appointed Director of Geron Corp. As of November 14, 2026, Geron Corp has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on March 26, 2026, naming 2 appointments (Form 8-K, March 26, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Geron Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Geron Corp reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-03-26. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Geron Corp files it.
Layoffs on record: about 260 jobs, latest 2025-12-16 (layoff filings and notices).
Also on the record for Geron Corp
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 10, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by RA Capital Management, L.P. | 9.9% of the class | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.6% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | 4.95% of the class | 5%+ stakes | Source |
| May 8, 2026 | Stake report, Schedule 13G/A, by Soleus Capital Master Fund, L.P. | 6.5% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| March 3, 2026 | Stake report, Schedule 13G, by Soleus Capital Master Fund, L.P. | 5.2% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | 5.09% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Deep Track Capital, LP | 6.75% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Geron Corp now and the warning signs.
Free to see. No signup.
Keep reading
More on Geron Corp and the records around it.
Geron Corp elsewhere on the record
- 5%+ stake filings Nov 2026
- Layoff notices Dec 2025
- Who owns it
Companies that share a holder
- Soleus Capital Master Fund, L.P. also filed stake reports on 24 other companies: Beta Bionics, Inc. (Nov 2026), Evolus, Inc (Nov 2026), INSPIRE MEDICAL SYSTEMS, INC. (Nov 2026)
- Deep Track Capital, LP also filed stake reports on 60 other companies: Mentari Therapeutics, Inc. (Nov 2026), Alector, Inc. (Oct 2026), TCGX Acquisition Corp. II (Oct 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Evommune, Inc. (Nov 2026), Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026)
Watch Geron Corp
Get an email when Geron Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Geron Corp?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Geron Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Geron Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
11 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-03-26 | In | Director | 8-K, 2026-03-26 | ||
| 2026-03-26 | In | 8-K, 2026-03-26 |
Who leads Geron Corp, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Patricia S. Andrews, appointed (filed 2026-03-26).
New leaders reset buying decisions — get the Full Report on Geron Corp: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Geron Corp, with the record behind each one.
Find candidates like Director at Geron CorpEvery change, in the filing's words
Appointed: Patricia S. Andrews, Director
On March 25, 2026, the Board of Directors (the "Board") of Geron Corporation (the "Company"), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Patricia S. Andrews and Constantine Chinoporos to the Board, in each case effective immediately, and each as a Class III director for a term expiring at the Company's 2026 Annual Meeting of Stockholders (the "2026 Annual Meeting").
Appointed: Patricia S. Andrews
In connection with her election to the Board, Ms. Andrews was appointed as a member of the Audit Committee of the Board with immediate effect.
- Each of Ms. Andrews and Mr. Chinoporos will receive cash and equity compensation for their respective service on the Board and its committees in accordance with the Company's standard compensatory arrangements for non-employee directors as described under the section titled "Compensation of Directors" in the Company's definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on April 8, 2025.
- In connection with their respective elections, the Company and each of Ms. Andrews and Mr. Chinoporos will enter into the Company's standard form of indemnification agreement.
- Pursuant to the terms of the indemnification agreement, the Company may be required, among other things, to indemnify each of Ms. Andrews and Mr. Chinoporos for certain expenses, including attorneys' fees, judgments, fines and settlement amounts incurred by them in any action or proceeding arising out of their service as directors of the Company.
- Biographical information for each of Ms. Andrews and Mr. Chinoporos is as follows: Ms. Andrews currently serves as a member of the Board of Directors of Glenmark Pharmaceuticals Limited, and as a director of its wholly-owned subsidiary, Ichnos Glenmark Innovation (IGI), positions she has held since August 2025.
Tools for this story
Each opens in a new tab, filled in for Geron Corp. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
